About Forte Biosciences, Inc.
https://www.fortebiorx.comForte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
CEO
Paul A. Wagner
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-28 | Reverse | 1:25 |
| 2020-06-16 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FRED ALGER MANAGEMENT, LLC
Shares:1.64M
Value:$52.5M
FEDERATED HERMES, INC.
Shares:1.64M
Value:$52.48M
JANUS HENDERSON GROUP PLC
Shares:1.4M
Value:$45.05M
Summary
Showing Top 3 of 47
About Forte Biosciences, Inc.
https://www.fortebiorx.comForte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $18.37M ▲ | $-17.68M ▼ | 0% | $-0.99 ▼ | $-17.66M ▼ |
| Q2-2025 | $0 | $11.56M ▼ | $-11.25M ▲ | 0% | $-0.96 ▲ | $-11.56M ▲ |
| Q1-2025 | $0 | $16.11M ▲ | $-15.66M ▼ | 0% | $-1.37 ▼ | $-16.11M ▼ |
| Q4-2024 | $0 | $7.34M ▼ | $-7.16M ▲ | 0% | $-1.12 ▲ | $-7.14M ▲ |
| Q3-2024 | $0 | $8.62M | $-8.39M | 0% | $-4.54 | $-8.62M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $93.41M ▼ | $97.09M ▼ | $12.99M ▲ | $84.1M ▼ |
| Q2-2025 | $106.14M ▲ | $107.78M ▲ | $9.17M ▲ | $98.61M ▲ |
| Q1-2025 | $45.86M ▼ | $47.46M ▼ | $9.03M ▼ | $38.43M ▼ |
| Q4-2024 | $58.37M ▲ | $61.56M ▲ | $9.08M ▲ | $52.48M ▲ |
| Q3-2024 | $16.36M | $17.95M | $8.58M | $9.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-17.68M ▼ | $-14M ▼ | $-55K ▼ | $1.32M ▼ | $-12.73M ▼ | $-14.05M ▼ |
| Q2-2025 | $-11.25M ▲ | $-10.06M ▲ | $0 ▼ | $70.35M ▲ | $60.29M ▲ | $-10.06M ▲ |
| Q1-2025 | $-15.66M ▼ | $-10.36M ▼ | $36.29M ▲ | $-2.32M ▼ | $23.61M ▲ | $-10.42M ▼ |
| Q4-2024 | $-7.16M ▲ | $-10.01M ▼ | $-35.99M ▼ | $51.88M ▲ | $5.88M ▲ | $-10.04M ▼ |
| Q3-2024 | $-8.39M | $-8.13M | $0 | $-2K | $-8.13M | $-8.13M |
CEO
Paul A. Wagner
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-28 | Reverse | 1:25 |
| 2020-06-16 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FRED ALGER MANAGEMENT, LLC
Shares:1.64M
Value:$52.5M
FEDERATED HERMES, INC.
Shares:1.64M
Value:$52.48M
JANUS HENDERSON GROUP PLC
Shares:1.4M
Value:$45.05M
Summary
Showing Top 3 of 47